Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000860980 | SCV001001172 | benign | EGFR-related lung cancer | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001544693 | SCV001763868 | likely benign | not provided | 2020-09-15 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001356543 | SCV002069901 | benign | not specified | 2021-07-26 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001544693 | SCV002545514 | benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | EGFR: BP4, BP7, BS1, BS2 |
ARUP Laboratories, |
RCV001544693 | SCV004563086 | benign | not provided | 2023-10-16 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001544693 | SCV005227365 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Department of Pathology and Laboratory Medicine, |
RCV001356543 | SCV001551744 | benign | not specified | no assertion criteria provided | clinical testing | The EGFR p.Gly503Gly variant was identified in the literature in a Korean cohort of 27 lung cancer cases (frequency: 0.41) and 27 controls (frequency: 0.41) (Choi_2007_PMID:12956637). The variant was also identified in a case report of an individual with suspected plasma cell neoplasm (Peterson_2019_PMID:31320253). The variant was identified in dbSNP (ID: rs17336800), ClinVar (classified as benign by Invitae) and LOVD 3.0, but was not identified in Cosmic. The variant was identified in control databases in 2092 of 267912 chromosomes (14 homozygous) at a frequency of 0.007809 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (Finnish) in 348 of 24930 chromosomes (freq: 0.01396), European (non-Finnish) in 1370 of 117988 chromosomes (freq: 0.01161), Other in 75 of 6696 chromosomes (freq: 0.0112), Latino in 163 of 35096 chromosomes (freq: 0.004644), Ashkenazi Jewish in 24 of 9852 chromosomes (freq: 0.002436), South Asian in 67 of 30502 chromosomes (freq: 0.002197) and African in 45 of 23606 chromosomes (freq: 0.001906), but was not observed in the East Asian population. The p.Gly503Gly variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, three of four in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing and the creation of a new 5' splice site. However, this has not been confirmed by RNA analysis and is not predictive enough to assume pathogenicity. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. |